A relatively new disease with particular strength in the New York City area but also in 12 U.S. states has seen 617 cases as of time of writing – with particular strength in weakened patients and those in long-term facilities. Because the fungus is detectable only with complex lab tests such as mass spectrometry, sequencing […]
Pittcon 2019 now in its 70th year, meets in Philadelphia this week. The meeting is an opportunity to showcase improvements in laboratory technology. While mass spectrometry and liquid chromatography are key areas for vendors, this year’s meeting will feature a large demonstration space where vendors will show off spectrometry, software and even analyze common everyday […]
News came this week that the Department of Veterans Affairs awarded Foundation Medicine, a Cambridge, MA- based molecular testing company, a significant contract to provide genomic profiling for veterans helps to validate the growing use of NGS and liquid biopsy for diagnostics. The contract was reported to be at 111.5 million over five years. It […]
Next-generation sequencing (NGS) in diagnostics is rapidly growing, having made great strides since the conclusion of the Human Genome Project fifteen years ago. Increasingly rapid and effective testing capabilities for hereditary diseases, cancers, cardiac and respiratory conditions, neurodegenerative disorders, and even infectious disease, are either on the horizon or have arrived. The promise of DNA […]
Kalorama Information notes 4 trends in monoclonal antibodies (mAbs) – large protein molecules produced by white blood cells that seek out and destroy harmful foreign substances – topped $100 billion in 2017, according to Kalorama Information What’s Trending in Monoclonal Antibodies, examines the several types of monoclonal antibodies on the market and in development, looking at […]
New York City-based healthcare market researcher Kalorama Information details the top 10 liquid biopsy companies and their activities in a new report. The market, Kalorama says, is heterogeneous and very fragmented, with many companies commercializing various liquid biopsy diagnostic products and developing new ones for a broad range of applications. But a few top competitors […]
